XVARY Composite Score
72
/ 100
Average
Combines growth, value, risk, and momentum factors into a single institutional-grade score.
Start here if you're new
What it is
Haemonetics sells the machines and software that help collect plasma, manage blood, and guide bleeding treatment in hospitals.
How it gets paid
Last year Haemonetics made $1.4B in revenue. Plasma was the main engine at $0.98B, or 70% of sales.
Why it's growing
Revenue grew 4.0% last year. Revenue rose 191% vs. prior year and EPS rose 159%.
What just happened
Was loud: revenue hit $988M and EPS reached $2.46.
At a Glance
A balance sheet — strong enough to weather a downturn
45/100 earnings predictability — expect surprises
14.0x trailing p/e — the market's not buying it — or you found a deal
14.0% return on capital — nothing to write home about
XVARY composite: 72/100 — average
What They Do
Haemonetics sells the machines and software that help collect plasma, manage blood, and guide bleeding treatment in hospitals.
This business wins because blood workflows are sticky. Once a hospital or plasma center installs the machines, trains staff, and plugs in the software, switching is painful. You can see that in the numbers: gross margin hit 59.7% and operating margin reached 16.3%, which means the installed base keeps paying.
How They Make Money
$1.4B
annual revenue · their business grew +4.0% last year
Plasma
$0.98B
+9.0%
Hospital
$0.25B
+6.0%
Blood Center
$0.11B
4.0%
Interventional Technologies
$0.06B
+12.0%
The Products That Matter
Blood collection and management devices
Blood Management Systems
$1.4B revenue
it's the entire $1.4B business, and it grew 4.2% last year. If growth re-accelerates or stalls, this is where you will see it first.
entire business
Key Numbers
$5.75
fy2027 eps est
$1B
fy2027 rev est
14.0x
trailing p/e
59.7%
gross margin
Gross profit kept about 59.7% of each revenue dollar.
Financial Health
A
Strength
- balance sheet grade A — very strong financial position
- risk rank 3 — safer than 50% of stocks
- price stability 25 / 100
- long-term debt $920M (22% of capital)
- net profit margin 18.5% — keeps 18 cents of every dollar in revenue
- return on equity 28% — $0.28 profit for every $1 investors have put in
A with balance sheet grade and net profit margin standing out. your money faces less risk here than at most public companies.
Total Return vs. Market
You invested $10000 in HAE 3 years ago → it's now worth $7780.
The index would have given you $14770.
source: institutional data · total return
What Just Happened
beat estimates
Was loud: revenue hit $988M and EPS reached $2.46.
Revenue rose 191% vs. prior year and EPS rose 159%, while gross margin reached 59.7%. The last reported quarterly EPS also beat estimates at $1.31 versus $1.23, a 6.5% surprise.
$988M
revenue
$2.46
eps
59.7%
gross margin
the number that mattered
Gross margin at 59.7% matters most because it shows this was not just a sales pop. The business got more profitable on each dollar sold.
-
Haemonetics recently completed a modest — yet promising — acquisition.
-
On january 9th, it finalized the buyout of vivasure medical limited, an irelandbased provider of percutaneous vessel closure technology.vivasure’s perqseal elite system seals large-bore surgical incisions into arteries (arteriotomies) and veins (venotomies) from inside the vessel, offering an advanced solution for heart and endovascular procedures.
-
The addition expands haemonetics’ suite of closure devices in a fast-growing market.the purchase price of 52 million euro (net of investments and loans by haemonetics) can reach 85 million euro contingent on certain milestones.
-
In 2025, vivasure submitted a premarket approval application with the u.s.
-
Fda for perqseal elite.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. Plain English, no spam.
Weekly updates
Earnings alerts
Plain English
No spam
What Could Go Wrong
The #1 risk is Vivasure integration and FDA approval for PerQseal Elite.
Med
PerQseal Elite still needs to clear the FDA path
Vivasure filed a premarket approval application in 2025. If that process drags or fails, the strategic logic behind the 52 million euro acquisition gets weaker fast.
The acquisition can cost up to 85 million euro with milestones. That is not thesis-breaking on its own, but it matters for a company with a roughly $3B market cap and only 4.0% revenue growth.
Med
4.0% growth leaves little room for execution mistakes
This is a profitable business, but not a fast-growing one. When revenue grows only 4.0%, a small slowdown can matter more than investors expect because the stock is being pitched on margin quality and EPS progression.
If revenue stalls while EPS estimates drift below the current $5.45 FY2026 view, the stock can stay cheap for a long time. Cheap is not the same thing as mispriced.
Med
The business is steadier than the stock
Price stability is only 25/100 and earnings predictability is 45/100. That means you can get sharp moves on routine updates because the market does not give HAE the benefit of the doubt.
The stock has already traded between $47 and $86 over the last 52 weeks. You are not buying a bunker stock, even with an A balance sheet.
with only 4.0% revenue growth and a 25/100 price-stability score, even a modest miss or FDA delay can move the stock harder than the income statement moves.
Source: institutional data · regulatory filings · risk analysis
Pay Attention To
Risk
PerQseal Elite approval path
The Vivasure thesis is not really about the press release. It is about whether the 2025 FDA application turns into an approved product.
Metric
Revenue growth above 4.0%
This stock gets more interesting if Haemonetics can push growth above the current 4.0% pace on a $1.4B base.
Earnings
Next quarterly EPS print
FY2025 EPS landed at $4.90 and FY2026 consensus sits at $5.45. The next print tells you whether that step-up is holding.
Trend
Institutional selling
149 buyers versus 169 sellers in 3Q2025 is not a collapse, but it is a reminder that big money has been more cautious than excited.
Analyst Rankings
short-term outlook
top 20%
momentum score 2. in human-speak, analysts think HAE has better-than-average odds of outperforming over the next year.
risk profile
average
stability score 3. This is middle-of-the-pack business risk, but the stock itself can still move around more than the balance sheet suggests.
chart momentum
top 20%
technical score 2. The tape has improved even though the three-year total return still looks rough.
earnings predictability
45 / 100
Expect some noise. This is not one of those businesses where you can model every quarter with clockwork precision.
Source: institutional data
Institutional Activity
149 buyers vs. 169 sellers in 3q2025. total institutional holdings: 51.5M shares.
Source: institutional data
Price Targets
3-5 year target range
$52
$141
$68
Current price
$97
Target midpoint · +42% from current · 3-5yr high: $135 (+95% · 19% ann'l return)
Want the deeper analysis?
The full deep dive: DCF model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
See plans from $5/moThe Deep Dive